Filing Flows › Viridian Therapeutics (VRDN) › Q3 2026 › vs Q2 2026
Viridian Therapeutics (VRDN) Q3 2026 vs Q2 2026 (quarter over quarter)
Viridian Therapeutics's revenue rose $25.5M (91×) from $284K in Q2 2026 to $25.8M in Q3 2026.
Viridian Therapeutics, Q3 2026: revenue $25.8M (-64% year over year), operating margin -401.8%, net loss $101M, operating cash flow −$92.8M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $25.8M | $284K | $25.5M | 91× |
| Other income, net | $2.3M | −$851K | $3.1M | — |
| Net loss | $101M | $127M | −$25.9M | -20% |
| Costs & expenses | $129M | $127M | $1.8M | +1% |
| Operating costs | $129M | $127M | $2.7M | +2% |
| Research & development | $70.1M | $71.6M | −$1.5M | -2% |
| SG&A | $57.6M | $55.0M | $2.6M | +5% |
| Operating cash sources | $110M | $122M | −$12.1M | -10% |
| Depreciation & amortization | $343K | $117K | $226K | +193% |
| Share-based compensation | $17.2M | $17.0M | $248K | +1% |
| Cash used in operations | $92.8M | $105M | −$12.6M | -12% |
| Net loss absorbed | $101M | $127M | −$25.9M | -20% |
| Working capital & other | $9.1M | −$4.7M | $13.8M | — |
Questions
How much did Viridian Therapeutics's revenue grow quarter over quarter in Q3 2026?
Viridian Therapeutics's revenue rose $25.5M (91×) from $284K in Q2 2026 to $25.8M in Q3 2026.